|
1
|
Basu P and Maier C: Phytoestrogens and
breast cancer: In vitro anticancer activities of isoflavones,
lignans, coumestans, stilbenes and their analogs and derivatives.
Biomed Pharmacother. 107:1648–1666. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Clarke M, Collins R, Darby S, Davies C,
Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al:
Effects of radio-therapy and of differences in the extent of
surgery for early breast cancer on local recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
366:2087–2106. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turashvili G and Brog E: Tumor
heterogeneity in breast cancer. Front Med (Lausanne). 4:2272017.
View Article : Google Scholar
|
|
4
|
Grantzau T and Overgaard J: Risk of second
non-breast cancer after radiotherapy for breast cancer: A
systematic review and meta-analysis of 762,468 patients. Radiother
Oncol. 114:56–65. 2015. View Article : Google Scholar
|
|
5
|
Bartelink H, Horiot JC, Poortmans PM,
Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad
WJ, Oei SB, Wárlám-Rodenhuis CC, et al: Impact of a higher
radiation dose on local control and survival in breast-conserving
therapy of early breast cancer: 10-Year results of the randomized
boost versus no boost EORTC 22881-10882 trial. J Clin Oncol.
25:3259–3265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balogh A, Persa E, Bogdándi EN, Benedek A,
Hegyesi H, Sáfrány G and Lumniczky K: The effect of ionizing
radiation on the homeostasis and functional integrity of murine
splenic regulatory T cells. Inflamm Res. 62:201–212. 2013.
View Article : Google Scholar
|
|
7
|
Deng G: Tumor-infiltrating regulatory T
cells: Origins and features. Am J Clin Exp Immunol. 7:81–87.
2018.PubMed/NCBI
|
|
8
|
Stanton SE and Disis ML: Clinical
significance of tumor-infiltrating lymphocytes in breast cancer. J
Immunother Cancer. 4:592016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takeya M and Komohara Y: Role of
tumor-associated macro-phages in human malignancies: Friend or foe?
Pathol Int. 66:491–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Du Y, Lin X, Qian Y, Zhou T and
Huang Z: CD4+CD25+ regulatory T cells in tumor immunity. Int
Immunopharmacol. 34:244–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cassetta L and Pollard JW: Repolarizing
macrophages improves breast cancer therapy. Cell Res. 27:963–964.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shou J, Zhang Z, Lai Y, Chen Z and Huang
J: Worse outcome in breast cancer with higher tumor-infiltrating
FOXP3+ Tregs : A systematic review and meta-analysis. BMC Cancer.
16:6872016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peranzoni E, Lemoine J, Vimeux L, Feuillet
V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J,
Ouakrim H, et al: Macrophages impede CD8 T cells from reaching
tumor cells and limit the efficacy of anti-PD-1 treatment. Proc
Natl Acad Sci USA. 115:E4041–E4050. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Buchan SL, Dou L, Remer M, Booth SG, Dunn
SN, Lai C, Semmrich M, Teige I, Mårtensson L, Penfold CA, et al:
Antibodies to costimulatory receptor 4-1BB enhance anti-tumor
immunity via T regulatory cell depletion and promotion of CD8 T
cell effector function. Immunity. 49:958–970 e957. 2018. View Article : Google Scholar
|
|
16
|
Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR
and Yang SM: Macrophages in tumor microenvironments and the
progression of tumors. Clin Dev Immunol. 2012:9480982012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed MM, Guha C, Hodge JW and Jaffee E:
Immunobiology of radiotherapy: New paradigms. Radiat Res.
182:123–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lumniczky K and Safrany G: The impact of
radiation therapy on the antitumor immunity: Local effects and
systemic consequences. Cancer Lett. 356:114–125. 2015. View Article : Google Scholar
|
|
19
|
Kulkarni SS and Canto C: The molecular
targets of resveratrol. Biochim Biophys Acta. 1852:1114–1123. 2015.
View Article : Google Scholar
|
|
20
|
Zhao Y, Tang H, Zeng X, Ye D and Liu J:
Resveratrol inhibits proliferation, migration and invasion via Akt
and ERK1/2 signaling pathways in renal cell carcinoma cells. Biomed
Pharmacother. 98:36–44. 2018. View Article : Google Scholar
|
|
21
|
Elshaer M, Chen Y, Wang XJ and Tang X:
Resveratrol: An over-view of its anti-cancer mechanisms. Life Sci.
207:340–349. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scarlatti F, Sala G, Ricci C, Maioli C,
Milani F, Minella M, Botturi M and Ghidoni R: Resveratrol
sensitization of DU145 prostate cancer cells to ionizing radiation
is associated to ceramide increase. Cancer Lett. 253:124–130. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y, Paik JH, Cho D, Cho JA and Kim CW:
Resveratrol induces the suppression of tumor-derived CD4+CD25+
regulatory T cells. Int Immunopharmacol. 8:542–547. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baatout S, Derradji H, Jacquet P, Ooms D,
Michaux A and Mergeay M: Enhanced radiation-induced apoptosis of
cancer cell lines after treatment with resveratrol. Int J Mol Med.
13:895–902. 2004.PubMed/NCBI
|
|
25
|
Jeong SH, Jo WS, Song S, Suh H, Seol SY,
Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative,
HS1793, overcomes the resistance conferred by Bcl-2 in human
leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo
YH, Seo SY, Lee SH, Ryu SR, Lee CM, Suh Hs and Jo WS: Resveratrol
analog, HS-1793 enhance anti-tumor immunity by reducing the
CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int
Immunopharmacol. 14:328–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi YJ, Heo K, Park HS, Yang KM and Jeong
MH: The resveratrol analog HS-1793 enhances radiosensitivity of
mouse-derived breast cancer cells under hypoxic conditions. Int J
Oncol. 49:1479–1488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeong MH, Yang KM, Jeong DH, Lee CG, Oh
SJ, Jeong SK, Lee KW, Jo YR and Jo WS: Protective activity of a
novel resveratrol analogue, HS-1793, against DNA damage in
137Cs-irradiated CHO-K1 cells. J Radiat Res. 55:464–475.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ,
Lee CW, Lee KY, Jeong MH and Jo WS: Interferon gamma induced by
resveratrol analog, HS-1793, reverses the properties of tumor
associated macrophages. Int Immunopharmacol. 22:303–310. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang WJ, Long LM, Yang N, Zhang QQ, Ji WJ,
Zhao JH, Qin ZH, Wang Z, Chen G and Liang ZQ: NVP-BEZ235, a novel
dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human
glioma stem cells in vitro. Acta Pharmacol Sin. 34:681–690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eberlein U, Scherthan H, Bluemel C, Peper
M, Lapa C, Buck AK, Port M and Lassmann M: DNA damage in peripheral
blood lymphocytes of thyroid cancer patients after radioiodine
therapy. J Nucl Med. 57:173–179. 2016. View Article : Google Scholar
|
|
32
|
Zhu Q, Wu X, Wu Y and Wang X: Interaction
between Treg cells and tumor-associated macrophages in the tumor
microenvironment of epithelial ovarian cancer. Oncol Rep.
36:3472–3478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu DP, Li Y, Meng X, Zhou T, Zhou Y, Zheng
J, Zhang JJ and Li HB: Natural antioxidants in foods and medicinal
plants: Extraction, assessment and resources. Int J Mol Sci.
18:E962017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sinha D, Sarkar N, Biswas J and Bishayee
A: Resveratrol for breast cancer prevention and therapy:
Preclinical evidence and molecular mechanisms. Semin Cancer Biol.
40-41:209–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
da Costa Araldi IC, Bordin FPR, Cadona FC,
Barbisan F, Azzolin VF, Teixeira CF, Baumhardt T, da Cruz IBM,
Duarte MMMF and Bauermann LF: The in vitro radiosensitizer
potential of resveratrol on MCF-7 breast cancer cells. Chem Biol
Interact. 282:85–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dewangan J, Tandon D, Srivastava S, Verma
AK, Yapuri A and Rath SK: Novel combination of salinomycin and
resveratrol synergistically enhances the anti-proliferative and
pro-apoptotic effects on human breast cancer cells. Apoptosis.
22:1246–1259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Barker HE, Paget JT, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sharma RA, Plummer R, Stock JK, Greenhalgh
TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, et
al: Clinical development of new drug-radiotherapy combinations. Nat
Rev Clin Oncol. 13:627–642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Malik A, Sultana M, Qazi A, Qazi MH,
Parveen G, Waquar S, Ashraf AB and Rasool M: Role of natural
radiosensitizers and cancer cell radioresistance: An update. Anal
Cell Pathol (Amst). 2016:61465952016.
|
|
40
|
Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo
KS, Song S, Suh H, Kwon TK, Park BS and Yoo YH: A novel resveratrol
analogue HS-1793 treatment overcomes the resistance conferred by
Bcl-2 and is associated with the formation of mature PML nuclear
bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol.
35:1353–1360. 2009.PubMed/NCBI
|
|
41
|
Cerda H, Delincee H, Haine H and Rupp H:
The DNA 'comet assay' as a rapid screening technique to control
irradiated food. Mutat Res. 375:167–181. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bausinger J and Speit G: The impact of
lymphocyte isolation on induced DNA damage in human blood samples
measured by the comet assay. Mutagenesis. 31:567–572. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Makkouk A and Weiner GJ: Cancer
immunotherapy and breaking immune tolerance: New approaches to an
old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar
|
|
44
|
Shiku H: Importance of CD4+ helper T-cells
in antitumor immunity. Int J Hematol. 77:435–438. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan
J, Li R, Zhao Q, Wei L, Yang T and Lu J: TGF-β regulates
hepatocellular carcinoma progression by inducing Treg cell
polarization. Cell Physiol Biochem. 35:1623–1632. 2015. View Article : Google Scholar
|
|
46
|
Son CH, Bae JH, Shin DY, Lee HR, Jo WS,
Yang K and Park YS: Combination effect of regulatory T-cell
depletion and ionizing radiation in mouse models of lung and colon
cancer. Int J Radiat Oncol Biol Phys. 92:390–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kachikwu EL, Iwamoto KS, Liao YP, DeMarco
JJ, Agazaryan N, Economou JS, McBride WH and Schaue D: Radiation
enhances regulatory T cell representation. Int J Radiat Oncol Biol
Phys. 81:1128–1135. 2011. View Article : Google Scholar :
|
|
48
|
Yang WC, Hwang YS, Chen YY, Liu CL, Shen
CN, Hong WH, Lo SM and Shen CR: Interleukin-4 supports the
suppressive immune responses elicited by regulatory T cells. Front
Immunol. 8:15082017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dardalhon V, Awasthi A, Kwon H, Galileos
G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, et
al: IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together
with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.
Nat Immunol. 9:1347–1355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Martin M, Lefaix J and Delanian S:
TGF-beta1 and radiation fibrosis: A master switch and a specific
therapeutic target? Int J Radiat Oncol Biol Phys. 47:277–290. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsu P, Santner-Nanan B, Hu M, Skarratt K,
Lee CH, Stormon M, Wong M, Fuller SJ and Nanan R: IL-10 Potentiates
Differentiation of Human Induced Regulatory T Cells via STAT3 and
Foxo1. J Immunol. 195:3665–3674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
